New Geron patent: Use of telomerase inhibitors for the treatment of MPD's and MPN's

[Fishermangents]

USPTO Applicaton #: #20170051287
Filing date: 23 February 2017

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms.

Summary of the invention:
'The invention provided herein discloses, inter alia, methods for using telomerase inhibitor compounds to treat and alleviate symptoms associated with myeloproliferative neoplasms such as Essential Thrombocythemia (ET), Polycythemia Vera (PV), Myelofibrosis (MF), and Acute Myelogenous Leukemia (AML) by targeting the neoplastic progenitor cells characteristic of these diseases. The invention provided herein also discloses, inter alia, methods for using telomerase inhibitor compounds to treat and alleviate symptoms associated with myelodysplastic syndromes (MDS) such as, for example, refractory anemia, refractory anemia with excess blasts, refractory cytopenia with multilineage dysplasia, refractory cytopenia with unilineage dysplasia, and chronic myelomonocytic leukemia by targeting the neoplastic progenitor cells responsible for producing the abnormally high numbers of cells characteristic of these diseases.'

The patent is set up broadly for myeloproliferative disorders and MPN's, but specifically menitons ET, PV, MF, AML, MDS and CML.